Shots:

• The P-III (QWINT-2 & 5) studies assessed efsitora vs degludec in T2D patients (n=928) using/not using GLP-1 agonist and T1D patients (n=692) on daily basal & multiple daily mealtime insulin, respectively, for 52wks.
• QWINT-2 reached its 1EP at wk.52, showing non-inferior A1C reduction (resulting A1C) of 1.34% (6.87%) vs 1.26% (6.95%); 1.30% (6.90%) vs 1.28% (6.92%) in those using GLP-1s & 1.38% (6.85%) vs 1.23% (6.99%) in those not using GLP-1s; subjects spent 45mins. more time in range. Results published in the NEJM
• QWINT-5 reached its 1EP at wk.26, showing non-inferior A1C reduction (resulting A1C) of 0.53% (7.37%) vs 0.59% (7.32%). Time in range during the 4wks. before wk.26 was 52.8% vs 53.1%. Results published in the Lancet

Ref: Eli Lilly | Image: Eli Lilly

Related News:- Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com